Xygenyx Inc

Neurocentria Co, based in Walnut Creek, CA, is a pioneering company dedicated to advancing the field of neuroscience. With a strong leadership team and a focus on scientific research, Neurocentria is known for its unique programs and innovative pipeline of products. Driven by a commitment to excellence, Neurocentria aims to make significant contributions to the understanding and treatment of neurological disorders. Through their cutting-edge science and dedication to improving lives, Neurocentria is poised to make a lasting impact in the field of neuroscience.Generated from the website

Reservoir Neuroscience, Inc. is a neuroscience lab located at 665 3rd St, Suite 250 in San Francisco, California. The company specializes in innovative research and development within the field of neuroscience. With a focus on advancing scientific knowledge and applications, Reservoir Neuroscience aims to contribute significantly to the understanding of the brain and its functions. Their work is positioned at the intersection of science and technology, promoting breakthroughs that could benefit various neurological conditions. Generated from the website

Santen is a wholly owned subsidiary of Santen Pharmaceutical. Located in Northern California s Napa Valley, the United States office is comprised of health care professionals with its senior management team totaling more than 20 years of industry experience, knowledge and expertise based exclusively in the ophthalmic field. In early 2004, Santen entered into a partnership agreement with VISTAKON Pharmaceuticals, granting VISTAKON the exclusive U.S. distribution rights to the Santen ophthalmic products QUIXIN 0.5%, BETIMOL 0.25% and 0.5%, and ALAMAST 0.1%, as well as its newest product IQUIX 1.5%, which gained FDA approval in March 2004. Santen is also actively pursuing technological alliances with a number of pharmaceutical companies and research institutes and has investments in an intraocular lens company. Santen opened its doors in the San Francisco Bay Area in 1993.